Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.Wang, X., Magnuson, S., Pastor, R., Fan, E., Hu, H., Tsui, V., Deng, W., Murray, J., Steffek, M., Wallweber, H., Moffat, J., Drummond, J., Chan, G., Harstad, E., Ebens, A.J.
(2013) Bioorg Med Chem Lett 23: 3149-3153
- PubMed: 23623490
- DOI: https://doi.org/10.1016/j.bmcl.2013.04.020
- Primary Citation of Related Structures:
4K0Y, 4K18, 4K1B
- PubMed Abstract:
Pim kinases are promising targets for the development of cancer therapeutics. Among the three Pim isoforms, Pim-2 is particularly important in multiple myeloma, yet is the most difficult to inhibit due to its high affinity for ATP. We identified compound 1 via high throughput screening. Using property-based drug design and co-crystal structures with Pim-1 kinase to guide analog design, we were able to improve potency against all three Pim isoforms including a significant 10,000-fold gain against Pim-2. Compound 17 is a novel lead with low picomolar potency on all three Pim kinase isoforms.
Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. email@example.com